Research Article
Evaluation of the Clinical Effects and Frequency of MEFV Gene Mutation in Patients with Inflammatory Bowel Disease
Table 1
Demographic and clinical characteristics of patients.
| | | CD () | UC () |
| | Demographic characteristics | Age () | | | | Duration of the disease (year, median) | 4 (8) | 5 (7) | | Age of onset of the disease () | | |
| | UC localization, (%) | Proctitis | — | 2 (3.6) | | Left colitis | — | 18 (32.7) | | Extensive colitis | — | 35 (63.6) |
| | CD localization, (%) | Ileal | 15 (33.4) | — | | Colonic | 1 (2.2) | — | | Ileocolic | 29 (64.4) | — |
| | CD behavior pattern, (%) | Inflammatory | 23 (51.1) | — | | Fibrotic | 8 (17.8) | — | | Fistulizing | 14 (31.1) | — | | Perianal disease | 12 (26.7) | — |
| | Disease activity, (%) | Remission | 41 (91.1) | 46 (83.6) | | Active | 4 (8.9) | 9 (16.4) | | Recurrent disease | 26 (57.7) | 19 (34.5) | | Steroid requirement | 34 (75.5) | 30 (54.5) | | Immunomodulator use requirement | 37 (82.2) | 26 (47.2) | | The necessity of using biological agents | 20 (44.4) | 10 (18.1) | | Surgical requirement | 14 (31) | 5 (11) |
| | Extraintestinal manifestations, (%) | Arthritis | 7 (15.6) | 4 (7.2) | | Pyoderma gangrenosum | 0 | 1 (1.8) | | Thromboembolic events | 0 | 1 (1.8) | | Ankylosing spondylitis | 2 (4.4) | 1 (1.8) | | Absent | 36 (80) | 48 (87.4) |
|
|
CD: Crohn’s disease; UC: ulcerative colitis; IBD: inflammatory bowel disease.
|
